Micurx Reaps $25M for Antimicrobials
By Marie Powers
Friday, August 23, 2013
Antimicrobial developer Micurx Pharmaceuticals Inc. raised $25 million in a Series B to fund the U.S. development of MRX-I, its oral oxazolidinone antibiotic targeting infections from multidrug-resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.